📊 CELUW Key Takeaways
Is Celularity Inc (CELUW) a Good Investment?
Celularity is in critical financial distress with negative stockholders' equity of -$20.1M, liabilities exceeding assets by $20.1M, and severe liquidity constraints (0.16x current ratio). Despite 138% revenue growth, the company is burning cash at an unsustainable rate (-$8.3M FCF) with massive operating losses (-$39.2M) that dwarf gross profits, indicating fundamental business model challenges in its pharmaceutical operations.
Celularity is showing strong top-line growth, but the underlying fundamentals remain severely impaired. Margins are deeply negative, free cash flow is negative, liquidity is critically weak, and negative equity indicates a highly stressed balance sheet. Unless the company can materially improve operating efficiency and secure stable financing, the current growth does not appear high quality or financially sustainable.
Why Buy Celularity Inc Stock? CELUW Key Strengths
- Strong revenue growth of 138% year-over-year showing market demand
- Positive gross margin of 30.1% indicating viable unit economics at the product level
- Improved diluted EPS by 76% YoY despite continued losses, suggesting cost structure improvements
- Revenue growth is very strong at +138.1% YoY, indicating commercial traction or expansion
- Gross profit is positive, showing the business can generate value above direct production costs
- Capital expenditure is low relative to losses, which limits additional cash drain from investment spending
CELUW Stock Risks: Celularity Inc Investment Risks
- Negative stockholders' equity of -$20.1M indicates technical insolvency and imminent need for capital restructuring or dilutive financing
- Critical liquidity crisis with only $120K cash against $134.3M liabilities and 0.16x current ratio, unable to fund operations or debt obligations
- Operating losses of -$39.2M far exceed gross profits, signaling unsustainable R&D, SG&A, and operating expenses despite revenue scaling
- Negative free cash flow of -$8.3M with -37% FCF margin indicates cash burn model is not sustainable without external funding
- $35.7M long-term debt burden with zero interest coverage capability given operating losses
- Operating and net margins are extremely negative, showing the business model is far from profitability
- Current ratio of 0.16x and cash of only $120K indicate acute liquidity risk
- Negative stockholders equity and meaningful long-term debt reflect a highly distressed capital structure
Key Metrics to Watch
- Cash balance and runway until insolvency without additional financing
- Path to operating profitability and timeline to positive operating cash flow
- Debt restructuring plans or additional capital raises and dilution impact
- Revenue growth sustainability and gross margin maintenance as company scales
- Quarterly operating cash burn relative to available liquidity
- Gross margin and operating loss trend as revenue scales
Celularity Inc (CELUW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CELUW Profit Margin, ROE & Profitability Analysis
CELUW vs Healthcare Sector: How Celularity Inc Compares
How Celularity Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Celularity Inc Stock Overvalued? CELUW Valuation Analysis 2026
Based on fundamental analysis, Celularity Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Celularity Inc Balance Sheet: CELUW Debt, Cash & Liquidity
CELUW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Celularity Inc's revenue has grown significantly by 154% over the 5-year period, indicating strong business expansion. The most recent EPS of $-11.02 indicates the company is currently unprofitable.
CELUW Revenue Growth, EPS Growth & YoY Performance
CELUW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $5.3M | -$6.5M | $-0.73 |
| Q2 2025 | $5.7M | -$6.5M | $-0.30 |
| Q1 2025 | $11.4M | -$19.8M | $-0.84 |
| Q3 2024 | $3.8M | -$16.1M | $-0.73 |
| Q2 2024 | $2.9M | -$6.5M | $-0.30 |
| Q1 2024 | $3.9M | -$22.0M | $-1.03 |
| Q3 2023 | $3.8M | $4.8M | $0.03 |
| Q2 2023 | $2.9M | -$15.0M | $-0.11 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Celularity Inc Dividends, Buybacks & Capital Allocation
CELUW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Celularity Inc (CIK: 0001752828)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CELUW
What is the AI rating for CELUW?
Celularity Inc (CELUW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CELUW's key strengths?
Claude: Strong revenue growth of 138% year-over-year showing market demand. Positive gross margin of 30.1% indicating viable unit economics at the product level. ChatGPT: Revenue growth is very strong at +138.1% YoY, indicating commercial traction or expansion. Gross profit is positive, showing the business can generate value above direct production costs.
What are the risks of investing in CELUW?
Claude: Negative stockholders' equity of -$20.1M indicates technical insolvency and imminent need for capital restructuring or dilutive financing. Critical liquidity crisis with only $120K cash against $134.3M liabilities and 0.16x current ratio, unable to fund operations or debt obligations. ChatGPT: Operating and net margins are extremely negative, showing the business model is far from profitability. Current ratio of 0.16x and cash of only $120K indicate acute liquidity risk.
What is CELUW's revenue and growth?
Celularity Inc reported revenue of $22.4M.
Does CELUW pay dividends?
Celularity Inc does not currently pay dividends.
Where can I find CELUW SEC filings?
Official SEC filings for Celularity Inc (CIK: 0001752828) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CELUW's EPS?
Celularity Inc has a diluted EPS of $-2.74.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CELUW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Celularity Inc has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CELUW stock overvalued or undervalued?
Valuation metrics for CELUW: ROE of N/A (sector avg: 15%), net margin of -300.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CELUW stock in 2026?
Our dual AI analysis gives Celularity Inc a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CELUW's free cash flow?
Celularity Inc's operating cash flow is $-8.2M, with capital expenditures of $161.0K. FCF margin is -37.0%.
How does CELUW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -300.1% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.16 (avg: 2).